Phenylimidazole derivatives as PDE10A enzyme inhibitors

摘要

This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

主权项

1. A compound having the structure I wherein HET is selected from the group consisting of imidazo[1,2-a]pyrimidine, [1,2,4]triazolo[1,5-a]pyrimidine, and [1,2,4]triazolo[1,5-c]pyrimidine, and wherein HET may optionally be substituted with up to three substituents R7-R9 individually selected from hydrogen, C1-C6 alkyl; halogen; cyano, halo(C1-C6)alkyl; aryl, alkoxy and C1-C6 hydroxyalkyl, -L- is a linker selected from —CH2—CH2—, —S—CH2—, —CH2—S— or —CH═CH—, R1 is selected from hydrogen, C1-C6 alkyl; C1-C6 alkyl(C3-C8)cycloalkyl; C1-C6 hydroxyalkyl, CH2CN, CH2C(O)NH2, C1-C6 arylalkyl, and C1-C6 alkyl-heterocycloalkyl, R2-R6 are selected individually from hydrogen, C1-C6alkoxy and halogen, and tautomers and pharmaceutically acceptable acid addition salts thereof, and polymorphic forms thereof.